Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$5.00 USD
-0.10 (-1.96%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $5.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.00 USD
-0.10 (-1.96%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $5.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum F VGM
Zacks News
GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss
by Zacks Equity Research
GW Pharmaceuticals (GWPH) reported a narrower-than-expected loss of 89 cents per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016).
Novo Nordisk Files Regulatory Application for Semaglutide
by Zacks Equity Research
Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.
Acceleron, Celgene Present Myelodysplastic Syndromes Data
by Zacks Equity Research
Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.
Alnylam Reports Positive Data on Fitusiran, Givosiran
by Zacks Equity Research
Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.
Pfizer (PFE) Presents Favorable Data on Leukemia Candidate
by Zacks Equity Research
Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).
Incyte Jakafi Positive in Pooled Analysis of Five-Year Data
by Zacks Equity Research
Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.
Alexion Presents Data from Ultra-Rare Blood Disorder Study
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) presented new data from a dose-escalation study on ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria at ASH.
Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug
by Zacks Equity Research
Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures.
bluebird Stock Up on Positive Interim Multiple Myeloma Data
by Zacks Equity Research
bluebird bio (BLUE) reported encouraging interim phase I data on its anti-BCMA CAR T cell candidate, bb2121, in relapsed/refractory multiple myeloma patients.
Merck KGaA (MKGAF) Expands Distribution Deal with Roche
by Zacks Equity Research
Merck (MKGAF) announced that it has expanded the distribution alliance with Roche (RHHBY) to include enzyme products ??? PCR and qPCR.
Heat Biologics Stock Falls on Negative Bladder Cancer Data
by Zacks Equity Research
Heat Biologics (HTBX) presented disappointing top-line phase II data from the bladder cancer study on its lead pipeline candidate, HS-410.
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in pediatric patients.
Ultragenyx (RARE) Reports Positive Phase II Study on UX007
by Zacks Equity Research
Ultragenyx (RARE) announced positive data from a phase II study on UX007 for the treatment of patients with long-chain fatty acid oxidation disorder (LC-FAOD).
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors
by Zacks Equity Research
Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.
Cytori Scleroderma Study Two-Year Follow-Up Data Published
by Zacks Equity Research
Cytori Therapeutics (CYTX) announced the publication of two year follow-up data from the scleroderma study.
Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile
by Zacks Equity Research
Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.
PhaseRx Soars on Orphan Drug Status for Rare Liver Disease
by Zacks Equity Research
PhaseRx (PZRX) received Orphan Drug status from the FDA for PRX-OTC for the treatment of rare liver disorder.
Amicus Provides Regulatory Update on Fabry Disease Drug
by Zacks Equity Research
Amicus Therapeutics, Inc. (FOLD) issued an update on the regulatory pathway for migalastat for the treatment of Fabry disease in the U.S.
Mallinckrodt (MNK) Tops Q4 Earnings on Solid Sales Growth
by Zacks Equity Research
Mallinckrodt Public Limited Company (MNK) reported adjusted earnings of $2.04 per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016), beating the Zacks Consensus Estimate of $1.98.
Zacks.com featured highlights: Electronic Arts, Vanda Pharmaceuticals, Advanced Energy Industries, Community Bank System and Lancaster Colony
by Zacks Equity Research
Zacks.com featured highlights: Electronic Arts, Vanda Pharmaceuticals, Advanced Energy Industries, Community Bank System and Lancaster Colony